Abstract
Background: Cladribine tablets 3.5 mg/kg (CT3.5) demonstrated strong and sustained efficacy versus placebo (pbo) in patients with relapsing multiple sclerosis in clarity and clarity ext. In clarity, patients with HDA had similar or better responses to CT3.5 than the overall study population. This post hoc analysis assessed efficacy and sustainability in patients with HDA who received CT3.5 in clarity and PBO in clarity ext (CT3.5-pbo subgroup).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
